PharmaFab revises manufacturing procedures
PharmaFab is revising its standard operating procedures for manufacturing following FDA 1warning letter. The June 15 letter followed inspection of PharmaFab's manufacturing facility in Grand Prairie, Tex. from Jan. 5 through Jan. 14. FDA's citations include inadequate procedures for handling reprocessed batches, conducting stability tests and preventing of objectionable microorganisms in drug products not required to be sterile. FDA noted that PharmaFab's responses were sufficient for five of the eight issues listed in the warning letter...
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.